𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hyperhomocysteinemia Due to Levodopa Treatment as a Risk Factor for Osteoporosis in Patients with Parkinson’s Disease

✍ Scribed by Seung Hun Lee; Mi Jung Kim; Beom-Jun Kim; Sung Reul Kim; Sail Chun; Hong-Kyu Kim; Jin Sook Ryu; Ghi Su Kim; Myoung Chong Lee; Sun Ju Chung; Jung-Min Koh

Publisher
Springer
Year
2010
Tongue
English
Weight
236 KB
Volume
86
Category
Article
ISSN
1432-0827

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of piribedil as early combinati
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study
✍ Marc Ziegler; Alexandre Castro-Caldas; Susanna Del Signore; Olivier Rascol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 775 KB

## Abstract Piribedil is a non‐ergot D2/D3 agonist with a significant antagonist action on α2A and α2C adrenergic receptor subtypes. This double‐blind placebo‐controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's dis